MLD-41

Last updated
MLD-41
MLD-41.svg
MLD-41 3D.png
Clinical data
Other namesMLD-41; N1-Methyl-Lysergic Acid Diethylamide; 1-Methyl-LSD; 1-Methyl-N,N-Diethyllysergamide; Methyl-LSD
Routes of
administration 		Oral [1] [2]
Drug class Serotonergic psychedelic; Hallucinogen
Identifiers
  • (8β)-N,N-Diethyl-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
Formula C21H27N3O
Molar mass 337.467 g·mol−1
3D model (JSmol)
  • O=C(N(CC)CC)[C@@H]3/C=C2/c4cccc1c4c(cn1C)C[C@H]2N(C3)C
  • InChI=1S/C21H27N3O/c1-5-24(6-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22(18)3)11-19(17)23(4)13-15/h7-10,12,15,19H,5-6,11,13H2,1-4H3/t15-,19-/m1/s1 Yes check.svgY
  • Key:VQZYKSWQIQANKB-DNVCBOLYSA-N Yes check.svgY
   (verify)

MLD-41, also known as 1-methyl-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). [1] [2] It has about 33% of the psychoactive potency of LSD. [1] [2] It has been studied with regard to cross-tolerance with LSD. [3] Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed. [4] [5]

Contents

Interactions

See also

References

  1. 1 2 3 Jacob P, Shulgin AT (1994). "Structure-activity relationships of the classic hallucinogens and their analogs" (PDF). NIDA Res Monogr. 146: 74–91. PMID   8742795. Archived from the original (PDF) on August 5, 2023.
  2. 1 2 3 Hoffer A (1965). "D-Lysergic acid diethylamide (LSD): A review of its present status". Clin Pharmacol Ther. 6: 183–255. doi:10.1002/cpt196562183. PMID   14288188.
  3. ↑ Abramson HA, Rolo A, Sklarofsky B, Stache J (January 1960). "Production of cross-tolerance to psychosis-producing doses of lysergic acid diethylamide and psilocybin". The Journal of Psychology. 49 (1): 151–154. doi:10.1080/00223980.1960.9916396.
  4. ↑ Majrashi M, Ramesh S, Deruiter J, Mulabagal V, Pondugula S, Clark R, Dhanasekaran M (2017). "Multipotent and Poly-therapeutic Fungal Alkaloids of Claviceps purpurea". In Agrawal DC, Tsay HS, Shyur LF, Wu YC, Wang SY (eds.). Medicinal Plants and Fungi: Recent Advances in Research and Development. Medicinal and Aromatic Plants of the World. Vol. 4. pp. 229–252. doi:10.1007/978-981-10-5978-0_8. ISBN   978-981-10-5977-3. ISSN   2352-6831. Metabolites of methysergide also exhibit pharmacological activity. Methylergometrine (one of methysergide's metabolites) is responsible for methysergide's therapeutic effects regarding migraine treatment (Müller-Schweinitzer and Tapparelli 1986). [...] The systemic availability of methysergide after oral administration is only 13%, due to a high degree of first-pass metabolism by N-1 demethylation to methylergometrine. After oral administration, the plasma concentrations of the metabolite are considerably higher than those of the parent drug, and the area under the plasma concentration curve (AUC) for methylergometrine is more than ten times greater than for methysergide.
  5. ↑ Müller-Schweinitzer E, Tapparelli C (March 1986). "Methylergometrine, an active metabolite of methysergide". Cephalalgia: An International Journal of Headache. 6 (1): 35–41. doi:10.1046/j.1468-2982.1986.0601035.x. PMID   3698092. S2CID   5778173.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.